Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Multiple Myeloma: Disparities in Access to Transplantation and Novel Therapy

October 7th 2022

Closing out their review of the barriers racial and ethnic minority groups encounter in receiving care, expert panelists address access to transplantation or novel therapy.

Multiple Myeloma: Disparities in Access to Specialized Care

October 7th 2022

Comprehensive discussion on access to specialized care and how racial and ethnic minority groups encounter barriers in this setting.

GPRC5D Antigen–Targeted CAR T-cell Therapy Induces Strong Response in Resistant Multiple Myeloma

October 3rd 2022

MCARH109, a CAR T-cell therapy targeting the “enigmatic” GPRC5D antigen, generated remissions in 70.6% of patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin Combination Elicits Encouraging ORRs in Relapsed/Refractory Multiple Myeloma

October 1st 2022

Belantamab mafodotin plus lenalidomide and dexamethasone showed durable responses in patients with relapsed/refractory multiple myeloma.

Multiple Myeloma: Disparities in Time to Diagnosis

September 30th 2022

Panelists address how racial and ethnic minority groups experience disparity in time to diagnosis within the multiple myeloma treatment pathway.

Societal Determinants of Health in Multiple Myeloma

September 30th 2022

Expert panelists shift their attention to how social determinants of multiple myeloma impact the treatment received by racial and ethnic minority groups.

Biological Determinants of Health in Multiple Myeloma

September 23rd 2022

Focused discussion on the biological determinants of multiple myeloma and how its prevalence is reflected in racial and ethnic minority groups.

Overview of Multiple Myeloma and Health Equity

September 23rd 2022

Joseph Mikhael, MD, spearheads an overview on the prevalence of multiple myeloma in racial and ethnic minority groups in the context of health equity.

FDA Panel Opposes Continued Approval of Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

September 22nd 2022

In a 14 to 2 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the benefit-risk profile of melphalan flufenamide is not favorable for the approved indicated population of patients with relapsed/refractory multiple myeloma.

Zevor-cel Elicits 100% ORR in Heavily Pretreated Relapsed/Refractory Myeloma

September 22nd 2022

The BCMA-directed CAR T-cell therapy zevorcabtagene autoleucel demonstrated a 100% objective response rate in heavily pretreated patients with relapsed/refractory multiple myeloma

Advice for Community Oncologists Treating Patients With R/R MM

September 15th 2022

Drs Lipe and Forsberg share advice for community oncologists and highlight unmet needs in the management of multiple myeloma.

Sequencing Therapies in Patients With R/R MM

September 15th 2022

Drs Forsberg and Lipe discuss strategies for sequencing therapies in relapsed/refractory multiple myeloma.

Selecting Patients for Treatment With DARA-Kd

September 15th 2022

Peter Forsberg, MD, offers insight into which patients with multiple myeloma are most suitable for treatment with the DARA-Kd regimen.

CANDOR Trial of Daratumumab Plus Carfilzomib and Dexamethasone in R/R MM

September 8th 2022

Brea Lipe, MD, and Peter Forsberg, MD, review the results of the CANDOR trial evaluating DARA-Kd regimen in R/R multiple myeloma.

Patient Profile 2: A 76-Year-Old Female with R/R MM

September 8th 2022

Brea Lipe, MD, and Peter Forsberg, MD, present the profile of a woman with relapsed/refractory multiple myeloma and share their opinions of the treatment regimen.

Real-World Data Highlight Efficacy of Ide-cel in Patients With Relapsed/Refractory Multiple Myeloma

September 6th 2022

A single-center study at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

Daratumumab Compliance Rates in Multiple Myeloma Maintained in Real-World Analysis

September 2nd 2022

Findings of a retrospective study demonstrated a high dosing compliance with daratumumab compared with approved indications for patients with multiple myeloma in the real-world setting.

Treatment of Patients With MM and High-Risk Cytogenetics

September 1st 2022

Dr Brea Lipe explains at what stages she orders genetic testing in patients with relapsed/refractory multiple myeloma and how she approaches the treatment of patients with high-risk cytogenetics.

Selecting the Appropriate Patients With MM for Treatment With Isa-Kd

September 1st 2022

Oncologists debate which patient populations most benefit from isatuximab plus carfilzomib and dexamethasone.

Single-Agent Belantamab Mafodotin Elicits Activity in Heavily Pretreated Patients With R/R Myeloma

September 1st 2022

Belantamab mafodotin monotherapy demonstrated anticancer activity with a tolerable safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma.